One of the main problems of the insulin hypoglycemia test (IHT) is the failure to achieve an adequate hypoglycemia (blood glucose, <45 mg/dl) with the standard dose of insulin used. The aim of the study was to identify by means of homeostasis model assessment (HOMA) the subjects at risk for hypoglycemia failure during IHT. For this purpose 32 patients in whom an IHT was performed were prospectively included. Receiver operating characteristics curve analyses were performed to assess the sensitivity and specificity of both insulinemia and HOMA. Eight patients (25%) did not reach adequate hypoglycemia. A serum insulin concentration above 17.7 microIU/ml or a HOMA value above 4.38 identified those subjects who would not reach adequate hypoglycemia with a probability of 75%. By contrast, when the levels of either insulinemia or HOMA were lower than the cut-off points mentioned above, the probability that individuals would reach sufficient hypoglycemia was 89.5%. In conclusion, quantitative estimate of insulin resistance by HOMA is a simple and reliable method that permits identification of individuals at risk of not reaching adequate hypoglycemia during IHT. In these patients, either alternative tests or a higher dose of insulin should be considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/jc.2003-031883 | DOI Listing |
Diabetol Metab Syndr
January 2025
Serviço de Endocrinologia (SEMPR) do Hospital das Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Background: Type 2 diabetes mellitus (T2D) is a global health concern with a rising prevalence, particularly in Brazil. Insulin therapy plays a crucial role in managing T2D, helping to maintain glucose and energy homeostasis. Moreover, early initiation of insulin is crucial for hyperglycemic control and prevention of chronic complications.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Medical Affairs, Astellas Pharma Inc, Tokyo, Japan.
Aims: Insulin therapy is a cornerstone in type 2 diabetes mellitus (T2DM) management, but its use is associated with several barriers, including hypoglycaemia, fear of injections and high costs. We compared the risk of insulin initiation and other treatment intensification between patients with T2DM newly treated with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus those newly treated with a dipeptidyl peptidase-4 inhibitor (DPP4i).
Materials And Methods: This Japanese retrospective cohort study was conducted between 1 January 2015 and 31 March 2023 using the JMDC Claims Database.
JCEM Case Rep
January 2025
Department of Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
A male neonate exhibited hallmark features of Beckwith-Wiedemann syndrome (BWS) including large for gestational age, macroglossia, multiple ear pits, and umbilical hernia. He had neonatal hypoglycemia, requiring a glucose infusion rate of 9.7 mg/kg/min.
View Article and Find Full Text PDFJ Diabetes Res
January 2025
Diabetes Center, Dallah Hospital, Riyadh, Saudi Arabia.
The study was aimed at assessing the role of the MiniMed780G system of glycemic control before, during, and after Ramadan among people with Type 1 diabetes (PwT1D). This is a single-center retrospective analysis of MiniMed780G system users aged 14 years and above whose glycemic profiles were collected from February 21 to May 20, 2023, which corresponds to the Hijri months of Sha'ban, Ramadan, and Shawwal 1444/1445. Data was collected, processed, and analyzed in the framework of the Medtronic Galaxy service of the One Hospital Clinical Service (OHCS) program in Dallah Hospital, Riyadh, Saudi Arabia.
View Article and Find Full Text PDFIndian J Crit Care Med
January 2025
Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Background: Glycemic variability (GV) is the third domain of sepsis-induced dysglycemia, after hyperglycemia and hypoglycemia, potentially leading to adverse outcomes. This study analyzed the association of GV with in-hospital mortality and length of stay (LOS) in non-diabetic sepsis patients.
Materials And Methods: In this prospective observational study, non-diabetic sepsis patients were followed till day 14 of hospital stay, and blood glucose levels were assessed by finger-prick method (seven times per day) daily; clinico-laboratory and GV parameters [standard deviation (SD), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE)] were assessed on days 1, 3, 5, 7, 10, and 14 of admission.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!